| MDL | - |
|---|---|
| Molecular Weight | 641.67 |
| Molecular Formula | C33H50Cl2N2O6 |
| SMILES | COC1=C(OC)C(OC)=CC(/C=C/CCCN2CCN(CCC/C=C/C3=CC(OC)=C(OC)C(OC)=C3)CCC2)=C1.[H]Cl.[H]Cl |
K-7174 dihydrochloride (10 μM; 1 h) inhibits the adhesion by VCAM-1 and its ligand
[1]
.
K-7174 dihydrochloride (1-30 μM; 1 h) dose-dependently suppresses the VCAM-1 expression with an IC
50
value of 14 μM
[1]
.
K-7174 dihydrochloride (1-30 μM; 1 h) dose-dependently suppresses the induction of VCAM-1 mRNA by TNFα with an IC
50
value of 9 μM
[1]
.
K-7174 dihydrochloride (10-20 μM; 24 h) dose-dependently rescues Epo production by Hep3B cells
[2]
.
K-7174 dihydrochloride (2.5-30 μM; 24 h) inhibits the binding activity of GATA
[2]
.
K-7174 dihydrochloride (0-25 μM; 72 h) inhibits MM cells growth and induces cell apoptosis
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [3]
| Cell Line: | KMS12-BM, U266, and RPMI8226 cell lines |
| Concentration: | 0-25 μM |
| Incubation Time: | 72 h |
| Result: | Inhibited MM cells growth. |
Apoptosis Analysis [3]
| Cell Line: | KMS12-BM, U266, and RPMI8226 cell lines |
| Concentration: | 10 μM |
| Incubation Time: | 48 h |
| Result: | Significantly increased apoptosis of MM cells with the increasing percentage of annexin-V-positive cells. |
K-7174 dihydrochloride (30 mg/kg; i.p. once daily for 9 days) reverses the decreasing of hemoglobin concentrations and reticulocyte counts by IL-1β or TNF-α
[2]
.
K-7174 dihydrochloride (75 mg/kg; i.p. once daily for 14 days) inhibits the tumor growth in vivo
[3]
.
K-7174 dihydrochloride (50 mg/kg; p.o. once daily for 14 days) inhibits the tumor growth in vivo and shows a better effect than intraperitoneal injection
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | ICR mice with IL-β or TNF-α injection [2] |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneal injection; 30 mg/kg once daily for 9 days |
| Result: | Increased erythropoietin (Epo) production, reticulocyte counts, and hemoglobin (Hb) concentrations. |
| Animal Model: | NOD/SCID mice with murine xenograft [3] |
| Dosage: | 75 mg/kg |
| Administration: | Intraperitoneal injection; once daily for 14 days |
| Result: | Significantly decreased tumor volume, but showed a significant body weight reduction after 10 days. |
| Animal Model: | NOD/SCID mice with murine xenograft [3] |
| Dosage: | 50 mg/kg |
| Administration: | Oral gavage; once daily for 14 days |
| Result: | Showed an anti-myeloma activity. Porved oral administration is more effective than intraperitoneal injection. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
H 2 O : 15 mg/mL ( 23.38 mM ; Need ultrasonic and warming)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5584 mL | 7.7922 mL | 15.5843 mL |
| 5 mM | 0.3117 mL | 1.5584 mL | 3.1169 mL |
| 10 mM | 0.1558 mL | 0.7792 mL | 1.5584 mL |
Add each solvent one by one: PBS
Solubility: 10 mg/mL (15.58 mM); Clear solution; Need ultrasonic